Abeona Therapeutics

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Abeona Therapeutics sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 5 completed upper quartile by trial count

Abeona Therapeutics: 8 sponsored US clinical trials, none currently recruiting.

Abeona Therapeutics sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 4 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Epidermolysis Bullosa, with 3 trials.

Upper-quartile sponsor footprint

Abeona Therapeutics sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients

NCT05725018
TERMINATED

A Long-term Follow-up Study of Patients With MPS IIIB Treated With ABO-101

NCT04655911
COMPLETED Phase 3

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106
TERMINATED Phase 1

Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB

NCT03315182
COMPLETED Phase 1

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
COMPLETED Phase 2

A Trial of the Safety and Efficacy of EcoNail™ in the Treatment of Fungus Infections of the Great Toenail

NCT00385502
COMPLETED Phase 3

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563394
COMPLETED Phase 3

MSI-78 Topical Cream vs. Oral Ofloxacin in the Treatment of Infected Diabetic Ulcers

NCT00563433

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1
Phase 3 4

Therapeutic Areas

Epidermolysis Bullosa 3
Recessive Dystrophic Epidermolysis Bullosa 2
RDEB 1
Diabetic Foot Ulcers 1
Epidermolysis Bullosa Dystrophica 1

How the Abeona Therapeutics archive is shaped

8 indexed studies, none listed as recruiting (0% open); 5 completed (63%).

Phase mix: 4 late (III/IV) vs 3 early (I/II) (balanced across stages).

Top condition: Epidermolysis Bullosa (3 trials), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Abeona Therapeutics: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Abeona Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Abeona TherapeuticsAB ScienceAbbott Point of CareAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Aciex Therapeutics10xBio22nd Century Group23andMe3-C Institute for Social Development
Abeona Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Abeona Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Abeona Therapeutics page

8 registered trials is a research-attention snapshot, not an endorsement of Abeona Therapeutics or any single study.

  • None of Abeona Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Epidermolysis Bullosa is the condition Abeona Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Epidermolysis Bullosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Abeona Therapeutics pipeline card: 8 registered trials from official public datasets.Report a data error.